1. Home
  2. ASMB vs NCZ Comparison

ASMB vs NCZ Comparison

Compare ASMB & NCZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • NCZ
  • Stock Information
  • Founded
  • ASMB 2005
  • NCZ 2003
  • Country
  • ASMB United States
  • NCZ United States
  • Employees
  • ASMB N/A
  • NCZ N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • NCZ Finance Companies
  • Sector
  • ASMB Health Care
  • NCZ Finance
  • Exchange
  • ASMB Nasdaq
  • NCZ Nasdaq
  • Market Cap
  • ASMB 225.9M
  • NCZ 258.2M
  • IPO Year
  • ASMB 2010
  • NCZ N/A
  • Fundamental
  • Price
  • ASMB $37.28
  • NCZ $13.77
  • Analyst Decision
  • ASMB Strong Buy
  • NCZ
  • Analyst Count
  • ASMB 6
  • NCZ 0
  • Target Price
  • ASMB $43.40
  • NCZ N/A
  • AVG Volume (30 Days)
  • ASMB 133.7K
  • NCZ 533.0K
  • Earning Date
  • ASMB 11-10-2025
  • NCZ 01-01-0001
  • Dividend Yield
  • ASMB N/A
  • NCZ 12.16%
  • EPS Growth
  • ASMB N/A
  • NCZ N/A
  • EPS
  • ASMB N/A
  • NCZ N/A
  • Revenue
  • ASMB $37,191,000.00
  • NCZ N/A
  • Revenue This Year
  • ASMB $14.29
  • NCZ N/A
  • Revenue Next Year
  • ASMB N/A
  • NCZ N/A
  • P/E Ratio
  • ASMB N/A
  • NCZ N/A
  • Revenue Growth
  • ASMB 31.30
  • NCZ N/A
  • 52 Week Low
  • ASMB $7.75
  • NCZ $2.50
  • 52 Week High
  • ASMB $39.71
  • NCZ $3.15
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 66.12
  • NCZ 51.74
  • Support Level
  • ASMB $35.50
  • NCZ $13.15
  • Resistance Level
  • ASMB $39.65
  • NCZ $13.81
  • Average True Range (ATR)
  • ASMB 2.14
  • NCZ 0.28
  • MACD
  • ASMB 0.05
  • NCZ -0.02
  • Stochastic Oscillator
  • ASMB 72.27
  • NCZ 57.77

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About NCZ Virtus Convertible & Income Fund II of Beneficial Interest

Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.

Share on Social Networks: